Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07158411 · ClinicalTrials.gov registry record · Phase 1
Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2)
A Phase 1 study, sponsored by Deciphera Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT07158411 is a Phase 1 study that has completed, run by Deciphera Pharmaceuticals. The registered enrollment target is 22 participants.
The verdict
NCT07158411, a Phase 1 study, has completed, sponsored by Deciphera Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the effect of multiple doses of vimseltinib on the pharmacokinetics (PK) of a clinical OCT2 substrate (metformin) in healthy male participants. This study will also assess the safety and tolerability when vimseltinib is co-administered with the clinical OCT2 substrate (metformin) in healthy male participants. This study will last approximately 25 days.
Interventions
- DRUG Metformin
- DRUG Vimseltinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2025-11-20 |
| Est. Completion | 2026-01-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07158411
The ClinicalTrials.gov registry entry for NCT07158411 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Deciphera Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Metformin is the first listed.
NCT07158411 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07158411 about?
NCT07158411 is a clinical study titled "Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2)". The main purpose of this study is to evaluate the effect of multiple doses of vimseltinib on the pharmacokinetics (PK) of a clinical OCT2 substrate (metformin) in healthy male participants. This study will also assess the safety and tolerability when vimseltinib is co-administered with the clinical ...
What is the current status of trial NCT07158411?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2025-11-20. Estimated completion is 2026-01-30.
What interventions are being tested in trial NCT07158411?
The interventions under investigation include: Metformin (DRUG), Vimseltinib (DRUG).
Who is sponsoring clinical trial NCT07158411?
This trial is sponsored by Deciphera Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.